Changes in inflammatory and coagulation biomarkers: A randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 1, 2011, Pages 36-43

  Baker, Jason V ^a,b   Neuhaus, Jacqueline ^a   Duprez, Daniel ^a   Kuller, Lewis H ^c   Tracy, Russell ^d   Belloso, Waldo H ^e   De Wit, Stephane ^f   Drummond, Fraser ^g   Lane, H Clifford ^h   Ledergerber, Bruno ⁱ   Lundgren, Jens ^j   Nixon, Daniel E ^k   Paton, Nicholas I ^l   Neaton, James D ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^f SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

^k VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^l MEDICAL RESEARCH COUNCIL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD4 ANTIGEN; D DIMER; INTERLEUKIN 6; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD CLOTTING; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INHIBITION;

ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; BLOOD COAGULATION; C-REACTIVE PROTEIN; CD4 LYMPHOCYTE COUNT; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HIV INFECTIONS; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; TIME FACTORS; VIRAL LOAD;

EID: 78650682935     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f7f61a     Document Type: Article

References (45)

1. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355: 2283-2296.
2. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5:e203.
3. Emery S, Neuhaus J, Phillips A, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133-1144.
4. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144:537-547.
5. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6, C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506-512.
6. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentrations of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;2000:1767.
7. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med. 2003;114:180-187.
8. Sakkinen PA, Macy EM, Callas PW, et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol. 1999; 149:261-267.
9. Smith KY, Fine DM, Patel P, et al. Similarity in efficacy and safety of abacavir/lamivudine (ABC/3TC) compared to tenofovir/emtricitabine (TDF/FTC) in combination with QD lopinavir/ritonavir (LPV/r) over 96 weeks in the HEAD Study. 17th International AIDS Conference, Mexico City. 2008; Abstract LBPE 1138.
10. Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009;23:929-939.
11. Van Vonderen MG, Hassink EA, Van Agtmael MA, et al. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J Infect Dis. 2009;199:1186-1194.
12. Wolf K, Tsakiris DA, Weber R, et al. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis. 2002;185:456-562.
13. Knudsen LS, Christensen IJ, Lottenburger T, et al. Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers. 2008;13:59-78.
14. El-Sadr WM, Grund B, Neuhaus J, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008;149:289-299.
15. Tracy RP. Thrombin, inflammation, and cardiovascular disease. Chest. 2003;124:49S-57S.
16. Smith A, Patterson C, Yarnell J, et al. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation. 2005;112: 3080-3087.
17. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-2639.
18. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5:e78.
19. Association between activation inflammatory and coagulation pathways and mortality during long-term follow up in SMART. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa.
20. Does activation in inflammatory and coagulation pathways independently predict the development of opportunistic disease in patients with HIV infection? 16th Conference on Retroviruses and Opportunistic Infection 2009; Montreal, CA.
21. 3. J Acquir Immune Defic Syndr. 2007;44:179-187.
22. Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22: 841-848.
23. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43: 27-34.
24. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS. 2006;20:741-749.
25. Serious fatal and non-fatal non-AIDS-defining illnesses in Europe. 16th Conference on Retroviruses and Opportunistic Infections February 8-11, 2009; Montreal, CA.
26. Young EM, Considine RV, Sattler FR, et al. Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy. Cardiovasc Toxicol. 2004;4:179-186.
27. Saif MW, Greenberg B. HIVand thrombosis: a review. AIDS Patient Care STDs. 2001;15:15-24.
28. Shen YM, Frenkel EP. Thrombosis and a hypercoagulable state in HIV-infected patients. Clin Appl Thromb Hemost. 2004;10:277-280.
29. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788-1795.
30. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-1371.
31. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214:231-241.
32. Bussolino F, Mitola S, Serini G, et al. Interactions between endothelial cells and HIV-1. Int J Biochem Cell Biol. 2001;33:371-390.
33. Decrion AZ, Dichamp I, Varin A, et al. HIV and inflammation. Curr HIV Res. 2005;3:243-259.
34. Lehmann C, Harper JM, Taubert D, et al. Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients. J Acquir Immune Defic Syndr. 2008;48:522-530.
35. Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS. 2008;22:707-715.
36. Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr. 2008;48:142-148.
37. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23:1059-1067.
38. French MA, King MS, Tschampa JM, et al. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis. 2009; 200:1212-1215.
39. Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010;115:161-167.
40. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62. (Pubitemid 40075680)
41. Boger MS, Shintani A, Redhage LA, et al. Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr. 2009;52:480-487.
42. INSIGHT/SMART and DAD Study Investigators. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17-24.
43. Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS. 2008;22:707-715.
44. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
45. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118:e29-e35.